Skip to main content
Caplight Logo









Exogenus Therapeutics

Exogenus Therapeutics

Private
CantanhedeHealthcare & Life Scienceshttps://www.exogenus-t.com/

Last Round

Strategic

Apr 24, 2024

Total Funding Raised

$1.32M

Company Overview

Exogenus Therapeutics is a biotechnology company developing an exosome-based platform technology designed to offer a pipeline of therapeutic products for skin and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

extracellular vesiclesexosomesregenerative medicineexosome therapycell-free therapybiotechnologyumbilical cord bloodbiologicsimmunomodulationtissue regenerationanti-inflammatory therapychronic wound healingfibrotic diseasesosteoarthritispre-clinical developmentGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exogenus Therapeutics Comparables

Compare Exogenus Therapeutics with similar companies based on industry and business-model similarity.

Exogenus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lysatpharma GmbH
84%
ConvEyXO
83%
RION
82%

Exogenus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicApr 24, 2024
GrantNov 9, 2022
GrantDec 30, 2019
SeedDec 10, 2015
Pre SeedAug 1, 2015

Exogenus Therapeutics Investors

Notable investors and investment history

Exogenus Therapeutics investors
InvestorRounds
European Union's Horizon Research and Innovation programGrant
3xP GlobalStrategic
COHiTEC ProgramAccelerator
Criteria Capital RiscPre Seed, Seed
Blue Bio ValueGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 1680% from 15 to 267.

  • Dec 5, 2024

    Grew 40% QoQ from 10 to 14 employees.

Exogenus Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Exogenus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exogenus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCantanhede
Employee Range13
Year Founded2015
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?